1. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
   Devika Rao et al, 2019, Oncotarget CrossRef
2. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
   Stephanie Smith et al, 2007, Journal of Clinical Oncology CrossRef
3. Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
   Adriana Handra-Luca et al, 2007, Clinical Cancer Research CrossRef
4. Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
   Annamaria Ruzzo et al, 2006, Journal of Clinical Oncology CrossRef
5. Polymorphisms inXRCC1,XRCC3, andCCND1and Survival After Treatment for Metastatic Breast Cancer
   Mary A. Bewick et al, 2006, Journal of Clinical Oncology CrossRef
6. Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
   Dianke Yu et al, 2008, Clinical Cancer Research CrossRef
7. Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer
   Daniela F. Giachino et al, 2007, Clinical Cancer Research CrossRef
8. Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
   Annamaria Ruzzo et al, 2007, Journal of Clinical Oncology CrossRef